Blog
SPAC company AlphaVEST, which focuses on acquiring target enterprises in China, releases important information disclosure

AlphaVest Acquisition Corp is a blank check company, registered on January 14, 2022 as an exempted company in the Cayman Islands, for the purpose of merging with one or more businesses, share exchanges, asset acquisitions, share purchases, reorganizations or similar business combinations (the “Business Combination”).
We may pursue acquisitions or business combinations with target companies in any business or industry, and such companies or targets may benefit from the expertise and capabilities of our management team.
Our efforts in identifying potential target businesses will not be limited to a specific geographic region, although we intend to focus primarily on businesses in Asia.
To date, we have not generated any revenue, and we do not expect to generate operating revenue until we complete a Business Combination.
The Company is a company in the early and emerging growth stage and, as such, the Company faces all risks associated with companies in the early and emerging growth stage.
On February 7, 2022, our AlphaVest Holdings LLC (our “Sponsor”) acquired 1,725,000 founder shares for an aggregate purchase price of $25,000, representing 20% of the issued and outstanding shares of our common stock after our initial public offering (as defined below).
We also issued 125,000 founder shares (the “EBC Founder Shares”) to EarlyBirdCapital, Inc. on July 11, 2022, for an aggregate purchase price of $1,750. Pursuant to FINRA Manual Rule 5110, FINRA treats the EBC Founder Shares as underwriter compensation. The EBC Founder Shares may not be sold, transferred or assigned prior to the completion of an initial Business Combination (except for transfers to permitted transferees of the founder shares, and such transferees must agree to the same terms and restrictions as those applicable to the founder shares, each as set forth herein).
For the year ended December 31, 2022, the Company had not commenced any operations. All activities for the year ended December 31, 2022 were related to the Company’s formation and initial public offering (the “Initial Public Offering” or “IPO”) and identifying a business combination target. The Company will not generate any operating revenue until the completion of a Business Combination. The Company will generate non-operating income in the form of interest income from the proceeds of the Initial Public Offering. The Company has selected December 31 as its fiscal year end.
The registration statement (the “Registration Statement”) for the Company’s Initial Public Offering was declared effective on December 19, 2022. On December 22, 2022, the Company completed the Initial Public Offering of 6,000,000 units (the “Units” and, with respect to the common stock included in the Units sold, the “Public Shares”) at a price of $10.00 per Unit, resulting in total proceeds of $60,000,000. Each Unit consists of one share of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and one right (the “Right”), with each Right entitling the holder to purchase one-tenth of a share of Common Stock. In addition, on December 29, 2022, the underwriters fully exercised their over-allotment option and completed the issuance and sale of additional Units. The Company issued an aggregate of 900,000 Units at a price of $10.00 per Unit, resulting in total proceeds of $9,000,000.
Contemporaneously with the completion of the Initial Public Offering, the Company completed the private sale of 365,000 Units (the “Private Units”) to the Sponsor at a purchase price of $10.00 per Private Unit, and 25,000 Private Units to EarlyBirdCapital, Inc. (“EBC”), generating total gross proceeds to the Company of $3,900,000. In connection with the underwriters’ exercise of the over-allotment option, on December 29, 2022, the Company sold 37,904 Private Units to the Sponsor at a purchase price of $10.00 per Private Unit and an additional 2,596 Private Units to EBC at a purchase price of $10.00 per Private Unit, generating additional total gross proceeds of $405,000 to the Company.
Of the proceeds the company received from its initial public offering and the sale of private placement units, $70,380,000 (or $10.20 per share of public stock) was deposited in a U.S. trust account with UBS, with Continental Stock Transfer & Trust Company serving as trustee. Approximately $550,000 of this amount was used to pay fees and expenses related to the completion of the initial public offering, including underwriting commissions, and an estimated $650,000 is available for working capital after the initial public offering.
Except for interest earned on funds held in the trust account that may be used by the company to satisfy its tax obligations, the proceeds from the initial public offering and the sale of private placement units held in the trust account will not be withdrawn from the trust account: (a) prior to the completion of our initial business combination; (b) upon the redemption of any public shares properly submitted in connection with a shareholder vote to amend our amended and restated certificate of incorporation, (i) modifying the substance or timing of our obligation to allow redemptions in connection with our initial business combination, or to redeem 100% of our public shares if we do not complete our initial business combination within 12 months (or up to 18 months if we extend the period to complete the business combination) after the closing of the initial public offering, or (ii) any other provision relating to shareholder rights or pre-initial business combination activities; and (c) if we are unable to complete our business combination within 12 months after the closing of the initial public offering (or up to 18 months if we extend the period to complete the business combination), redeem our public shares, subject to applicable laws.
Since the IPO, our only business activities have been identifying and evaluating suitable acquisition transaction candidates. The outbreak of the COVID-19 coronavirus has caused a widespread health crisis and adversely affected economies and financial markets around the world. Potential target companies may delay or terminate discussions with us regarding a potential business combination, regardless of whether the COVID-19 virus affects their business operations. The extent of the impact of the COVID-19 pandemic on our ability to seek a business combination will depend on future developments, which are highly uncertain and unpredictable, including possible new information regarding the severity of the COVID-19 pandemic, and actions to contain the COVID-19 pandemic or address its impacts, among other factors.
After the closing of the initial public offering, we will have up to 12 months to complete our initial business combination.
However, if we anticipate that we may be unable to complete our initial business combination within 12 months, we may, upon resolution by the board of directors and at the request of the sponsor, extend the period to complete our initial business combination for up to two additional three-month periods (for a total of up to 18 months from the date of the closing of our initial public offering).
Originally published on 金盒企业管理集团




